Ethosuximide (200 mg/kg) showed the strongest reduction of SWDs in both APP/PS1 (93% ± 4) and 3xTg-AD (83% ± 5) mice, with almost complete elimination of SWDs in the first several hours after the loading dose (Figure 4B,F). Here, APP is linked to Alzheimer disease.